The development of the 3D reconstructed human skin micronucleus (RSMN) assay is the first to overcome the limitations of traditional cell culture methods. It can provide a more biologically relevant result than standard 2D in vitro genotoxicity assays, since it provides a functional stratum corneum, which accounts for permeability and appears to have a normal dermal metabolic capability.
In the search for new antibiotics, researchers are taking an unusual approach: They are developing peptides, short chains of protein building blocks that effectively inhibit a key enzyme of bacterial metabolism. The road from gene to protein has an important stop along the way: ribonucleic acid, or RNA.
A Phase 2 clinical trial, described this week in the Journal of Clinical Oncology, tested a new protocol for treating a relatively rare form of brain cancer, primary CNS lymphoma, that may change the standard of care for this disease, according to doctors who led the research.
Talk about a comeback: A treatment pulled off the market 30 years ago has won Food and Drug Administration approval again as the only drug specifically designated to treat morning sickness. That long-ago safety scare, prompted by hundreds of lawsuits claiming birth defects, proved to be a false alarm.
The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs. Tumor antigens, unique proteins on the surface of a tumor, are potential targets for a normal immune response against cancer.
Scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream. By comparing this protein pump to a related protein involved in cystic fibrosis, the researchers also identified a compound that partially repairs the pump in laboratory tests.
There may be nearly four times as many people infected with the tropical disease dengue globally than was previously believed, according to a new study. The World Health Organization has estimated there are about 50 million to 100 million cases of dengue, also known as "break-bone fever," every year.
Scientists have found that a drug treatment administered at the earliest signs of a rare genetic disease could prevent the condition from developing in later life.
A new global plan aims to end most cases of polio by late next year, and essentially eradicate the paralyzing disease by 2018— if authorities can raise the $5.5 billion needed to do the work, health officials said.
Using the same strategy that a common virus employs to evade the human immune system, researchers have modified adult stem cells to increase their survival– with the goal of giving the cells time to exert their natural healing abilities.
Researchers reported that three-dimensional scaffolds used to culture Ewing’s sarcoma cells were effective at mimicking the environment in which such tumors develop.
A team of scientists has unveiled a new technique for vaccine design that could be particularly useful against HIV and other fast-changing viruses.
Researchers have investigated the effect that all seven botulinum toxins have on neuron survival, and they have discovered that not all botulinum toxins are equally safe for neurons.
Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study.
Two new studies shed light on the molecular biology of three blood disorders, leading to novel strategies to treat these diseases.
Until now most experimental vaccines against the highly lethal H5N1 avian influenza virus have lacked effectiveness. But a new vaccine has proven highly effective against the virus when tested in both mice and ferrets.
Have a heart problem? If it’s fixable, there’s a good chance it can be done without surgery, using tiny tools and devices that are pushed through tubes into blood vessels.
A team of scientists has determined and analyzed the high-resolution atomic structures of two kinds of human serotonin receptor.
Inflammation is stirring up headlines again. Anti-inflammatory aspirin prevented thousands more cancers. The anti-inflammatory “miracle molecule” resveratrol came back. Psychologists report inflammation is stoked by even minor tensions. And archaeologists say all this knowledge is long overdue, as even Egyptian mummies have clogged arteries. We have been plagued by inflammation since the time of the Pharaohs.
Research has uncovered a method to produce retinal cells from regenerative human stem cells without the use of animal products, proteins or other foreign substances.
Don't look for testing of the anthrax vaccine to begin in children any time soon. Controversy arose last year as experts debated whether such studies should be done to learn how to treat children in case of a bioterror attack.
In a small, preliminary study of regular migraine sufferers, scientists have found that measuring a fat-derived protein called adiponectin (ADP) before and after migraine treatment can accurately reveal which headache victims felt pain relief.
Researchers at Albert Einstein College of Medicine of Yeshiva University and the Icahn School of Medicine at Mount Sinai have found that macrophages – white blood cells that play a key role in the immune response– also help to both produce and eliminate the body’s red blood cells (RBCs). The findings could lead to novel therapies for diseases or conditions in which the red blood cell production is thrown out of balance. The study, conducted in mice, is published today in the online edition of the journal Nature Medicine.
Researchers have identified an elusive anti-cancer property of vitamin E that has long been presumed to exist, but difficult to find.
Researchers report that influenza virus-specific CD8+ T cells or virus-specific non-neutralizing antibodies are each relatively ineffective at conferring protective immunity alone. But, when combined, the virus-specific CD8 T cells and non-neutralizing antibodies cooperatively elicit robust protective immunity.